MedTrace Logo

Novel Treatment Option for Neuropathic Pain

NCT02490436 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2016-11-08

No results posted yet for this study

Summary

The purpose of this study is to determine whether the EGFR-inhibitor cetuximab is better than placebo for the treatment of neuropathic pain.

Conditions

  • Neuralgia
  • Complex Regional Pain Syndromes

Interventions

DRUG

Cetuximab

Randomized cross-over between cetuximab and placebo

DRUG

Placebo

Randomized cross-over between cetuximab and placebo

Sponsors & Collaborators

  • Frontier Science & Technology Research Foundation, Inc.

    collaborator INDUSTRY

  • Merck KGaA, Darmstadt, Germany

    collaborator INDUSTRY

  • Sorlandet Hospital HF

    lead OTHER_GOV

Principal Investigators

  • Christian Kersten, MD PhD · Center for Cancer Treatment, Sørlandet Hospital, Kristiansand

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02490436 on ClinicalTrials.gov